Pfizer & BioNTech’s COVID-19 vaccine is expected to receive FDA approval for adolescents ages 12 and older sometime this week. The expected approval comes from a Phase III trial in adolescents between the ages of 12 and 15 with 2,260 participants that demonstrated a 100% efficacy rate. Previously, the vaccine has received emergency use authorization (EUA) for adults 16 years and older. Albert Bourla, Chairman and Chief Executive Officer of Pfizer, stated, “We share the urgency to expand the authorization of our vaccine to use in younger populations and are encouraged by the clinical trial data from adolescents between the ages of 12 and 15.”

Read more here.

More on: